The growth of the contract manufacturing sector can be attributed to a number of factors, particularly the increasing popularity of outsourcing as a manufacturing option. Outsourcing allows drug developers to access expertise and capabilities they may not possess in-house, as well as generating time and cost efficiencies in many cases.
Contract manufacturers, like Pfizer CentreOne, serve as reliable partners for their customers, offering expertise that is not available in-house to guide a drug securely and efficiently from development to commercial manufacture. Our VP, global contract manufacturing leader, Tom Wilson, joined a group of industry leaders to discuss this sector's changing landscape.
Read the full article here.
